Does the media prefer AARD or CRMD?

In the previous week, CorMedix had 14 more articles in the media than Aardvark Therapeutics. MarketBeat recorded 20 mentions for CorMedix and 6 mentions for Aardvark Therapeutics. Aardvark Therapeutics' average media sentiment score of 1.26 beat CorMedix's score of 0.81 indicating that Aardvark Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aardvark Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CorMedix 6 Very Positive mention(s) 2 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is CTNM or AARD more profitable?

Contineum Therapeutics' return on equity of -24.73% beat Aardvark Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Contineum Therapeutics N/A -24.73% -23.51% Aardvark Therapeutics N/A -71.54% -64.94%

Does the media prefer CTNM or AARD?

In the previous week, Aardvark Therapeutics had 2 more articles in the media than Contineum Therapeutics. MarketBeat recorded 6 mentions for Aardvark Therapeutics and 4 mentions for Contineum Therapeutics. Aardvark Therapeutics' average media sentiment score of 1.26 beat Contineum Therapeutics' score of 0.62 indicating that Aardvark Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Contineum Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Aardvark Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation and earnings, AARD or RLMD?

Relmada Therapeutics is trading at a lower price-to-earnings ratio than Aardvark Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Aardvark Therapeutics N/A N/A -$57.59M -$3.21 N/A Relmada Therapeutics N/A N/A -$57.38M -$0.90 N/A

Is AARD or RLMD more profitable?

Relmada Therapeutics' return on equity of -47.52% beat Aardvark Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Aardvark Therapeutics N/A -71.54% -64.94% Relmada Therapeutics N/A -47.52% -43.97%

Does the media favor AARD or RLMD?

In the previous week, Relmada Therapeutics had 10 more articles in the media than Aardvark Therapeutics. MarketBeat recorded 16 mentions for Relmada Therapeutics and 6 mentions for Aardvark Therapeutics. Aardvark Therapeutics' average media sentiment score of 1.26 beat Relmada Therapeutics' score of 0.86 indicating that Aardvark Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aardvark Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Relmada Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor SPRY or AARD?

In the previous week, ARS Pharmaceuticals had 20 more articles in the media than Aardvark Therapeutics. MarketBeat recorded 26 mentions for ARS Pharmaceuticals and 6 mentions for Aardvark Therapeutics. Aardvark Therapeutics' average media sentiment score of 1.26 beat ARS Pharmaceuticals' score of 0.05 indicating that Aardvark Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ARS Pharmaceuticals 3 Very Positive mention(s) 1 Positive mention(s) 15 Neutral mention(s) 3 Negative mention(s) 2 Very Negative mention(s) Neutral Aardvark Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer BIOA or AARD?

In the previous week, Aardvark Therapeutics had 1 more articles in the media than BioAge Labs. MarketBeat recorded 6 mentions for Aardvark Therapeutics and 5 mentions for BioAge Labs. BioAge Labs' average media sentiment score of 1.36 beat Aardvark Therapeutics' score of 1.26 indicating that BioAge Labs is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioAge Labs 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Aardvark Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Aardvark Therapeutics (AARD) Competitors

$6.54 +0.13 (+2.03%)

Closing price 04:00 PM Eastern

Extended Trading

$6.52 -0.01 (-0.23%)

As of 07:34 PM Eastern

Compare

AARD vs. CRMD, CTNM, RLMD, SPRY, and BIOA

Should you buy Aardvark Therapeutics stock or one of its competitors? Aardvark Therapeutics's main competitors and comparable companies include CorMedix (CRMD), Contineum Therapeutics (CTNM), Relmada Therapeutics (RLMD), ARS Pharmaceuticals (SPRY), and BioAge Labs (BIOA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Aardvark Therapeutics compare to CorMedix?

Aardvark Therapeutics (NASDAQ:AARD) and CorMedix (NASDAQ:CRMD) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, earnings, analyst recommendations, valuation, dividends, media sentiment and institutional ownership.

Aardvark Therapeutics presently has a consensus target price of $16.30, indicating a potential upside of 149.24%. CorMedix has a consensus target price of $15.00, indicating a potential upside of 98.94%. Given Aardvark Therapeutics' higher possible upside, equities analysts clearly believe Aardvark Therapeutics is more favorable than CorMedix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aardvark Therapeutics	2 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.46
CorMedix	0 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.75

34.2% of CorMedix shares are held by institutional investors. 17.8% of Aardvark Therapeutics shares are held by company insiders. Comparatively, 3.5% of CorMedix shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

CorMedix has a net margin of 40.49% compared to Aardvark Therapeutics' net margin of 0.00%. CorMedix's return on equity of 41.90% beat Aardvark Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aardvark Therapeutics	N/A	-71.54%	-64.94%
CorMedix	40.49%	41.90%	21.30%

Aardvark Therapeutics has a beta of 3.81, meaning that its stock price is 281% more volatile than the broader market. Comparatively, CorMedix has a beta of 1.5, meaning that its stock price is 50% more volatile than the broader market.

In the previous week, CorMedix had 14 more articles in the media than Aardvark Therapeutics. MarketBeat recorded 20 mentions for CorMedix and 6 mentions for Aardvark Therapeutics. Aardvark Therapeutics' average media sentiment score of 1.26 beat CorMedix's score of 0.81 indicating that Aardvark Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aardvark Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
CorMedix	6 Very Positive mention(s)	2 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

CorMedix has higher revenue and earnings than Aardvark Therapeutics. Aardvark Therapeutics is trading at a lower price-to-earnings ratio than CorMedix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aardvark Therapeutics	N/A	N/A	-$57.59M	-$3.21	N/A
CorMedix	$311.71M	1.90	$163.05M	$2.13	3.54

Summary

CorMedix beats Aardvark Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Aardvark Therapeutics compare to Contineum Therapeutics?

Contineum Therapeutics (NASDAQ:CTNM) and Aardvark Therapeutics (NASDAQ:AARD) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, valuation, media sentiment, analyst recommendations, profitability, earnings, dividends and institutional ownership.

In the previous week, Aardvark Therapeutics had 2 more articles in the media than Contineum Therapeutics. MarketBeat recorded 6 mentions for Aardvark Therapeutics and 4 mentions for Contineum Therapeutics. Aardvark Therapeutics' average media sentiment score of 1.26 beat Contineum Therapeutics' score of 0.62 indicating that Aardvark Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Contineum Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Aardvark Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Aardvark Therapeutics has lower revenue, but higher earnings than Contineum Therapeutics. Contineum Therapeutics is trading at a lower price-to-earnings ratio than Aardvark Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Contineum Therapeutics	$50M	10.68	-$59.98M	-$1.73	N/A
Aardvark Therapeutics	N/A	N/A	-$57.59M	-$3.21	N/A

Contineum Therapeutics currently has a consensus target price of $20.25, indicating a potential upside of 42.71%. Aardvark Therapeutics has a consensus target price of $16.30, indicating a potential upside of 149.24%. Given Aardvark Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Aardvark Therapeutics is more favorable than Contineum Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Contineum Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Aardvark Therapeutics	2 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.46

Contineum Therapeutics has a beta of 0.74, suggesting that its stock price is 26% less volatile than the broader market. Comparatively, Aardvark Therapeutics has a beta of 3.81, suggesting that its stock price is 281% more volatile than the broader market.

Contineum Therapeutics' return on equity of -24.73% beat Aardvark Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Contineum Therapeutics	N/A	-24.73%	-23.51%
Aardvark Therapeutics	N/A	-71.54%	-64.94%

Summary

Aardvark Therapeutics beats Contineum Therapeutics on 9 of the 13 factors compared between the two stocks.

How does Aardvark Therapeutics compare to Relmada Therapeutics?

Aardvark Therapeutics (NASDAQ:AARD) and Relmada Therapeutics (NASDAQ:RLMD) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, risk, earnings, media sentiment and dividends.

In the previous week, Relmada Therapeutics had 10 more articles in the media than Aardvark Therapeutics. MarketBeat recorded 16 mentions for Relmada Therapeutics and 6 mentions for Aardvark Therapeutics. Aardvark Therapeutics' average media sentiment score of 1.26 beat Relmada Therapeutics' score of 0.86 indicating that Aardvark Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aardvark Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Relmada Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Aardvark Therapeutics presently has a consensus price target of $16.30, indicating a potential upside of 149.24%. Relmada Therapeutics has a consensus price target of $12.00, indicating a potential upside of 150.00%. Given Relmada Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Relmada Therapeutics is more favorable than Aardvark Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aardvark Therapeutics	2 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.46
Relmada Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75

Relmada Therapeutics is trading at a lower price-to-earnings ratio than Aardvark Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aardvark Therapeutics	N/A	N/A	-$57.59M	-$3.21	N/A
Relmada Therapeutics	N/A	N/A	-$57.38M	-$0.90	N/A

45.2% of Relmada Therapeutics shares are held by institutional investors. 17.8% of Aardvark Therapeutics shares are held by company insiders. Comparatively, 14.5% of Relmada Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Aardvark Therapeutics has a beta of 3.81, indicating that its stock price is 281% more volatile than the broader market. Comparatively, Relmada Therapeutics has a beta of 0.46, indicating that its stock price is 54% less volatile than the broader market.

Relmada Therapeutics' return on equity of -47.52% beat Aardvark Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aardvark Therapeutics	N/A	-71.54%	-64.94%
Relmada Therapeutics	N/A	-47.52%	-43.97%

Summary

Relmada Therapeutics beats Aardvark Therapeutics on 8 of the 13 factors compared between the two stocks.

How does Aardvark Therapeutics compare to ARS Pharmaceuticals?

ARS Pharmaceuticals (NASDAQ:SPRY) and Aardvark Therapeutics (NASDAQ:AARD) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, media sentiment, dividends, analyst recommendations, profitability and earnings.

ARS Pharmaceuticals has a beta of 0.98, meaning that its stock price is 2% less volatile than the broader market. Comparatively, Aardvark Therapeutics has a beta of 3.81, meaning that its stock price is 281% more volatile than the broader market.

In the previous week, ARS Pharmaceuticals had 20 more articles in the media than Aardvark Therapeutics. MarketBeat recorded 26 mentions for ARS Pharmaceuticals and 6 mentions for Aardvark Therapeutics. Aardvark Therapeutics' average media sentiment score of 1.26 beat ARS Pharmaceuticals' score of 0.05 indicating that Aardvark Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ARS Pharmaceuticals	3 Very Positive mention(s)	1 Positive mention(s)	15 Neutral mention(s)	3 Negative mention(s)	2 Very Negative mention(s)	Neutral
Aardvark Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

68.2% of ARS Pharmaceuticals shares are held by institutional investors. 33.8% of ARS Pharmaceuticals shares are held by company insiders. Comparatively, 17.8% of Aardvark Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Aardvark Therapeutics has a net margin of 0.00% compared to ARS Pharmaceuticals' net margin of -184.24%. Aardvark Therapeutics' return on equity of -71.54% beat ARS Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ARS Pharmaceuticals	-184.24%	-199.96%	-65.41%
Aardvark Therapeutics	N/A	-71.54%	-64.94%

Aardvark Therapeutics has lower revenue, but higher earnings than ARS Pharmaceuticals. ARS Pharmaceuticals is trading at a lower price-to-earnings ratio than Aardvark Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ARS Pharmaceuticals	$84.28M	6.66	-$171.30M	-$2.01	N/A
Aardvark Therapeutics	N/A	N/A	-$57.59M	-$3.21	N/A

ARS Pharmaceuticals currently has a consensus target price of $28.20, suggesting a potential upside of 399.12%. Aardvark Therapeutics has a consensus target price of $16.30, suggesting a potential upside of 149.24%. Given ARS Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe ARS Pharmaceuticals is more favorable than Aardvark Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ARS Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Aardvark Therapeutics	2 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.46

Summary

Aardvark Therapeutics beats ARS Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

How does Aardvark Therapeutics compare to BioAge Labs?

BioAge Labs (NASDAQ:BIOA) and Aardvark Therapeutics (NASDAQ:AARD) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, earnings, valuation, risk, profitability and dividends.

Aardvark Therapeutics has a net margin of 0.00% compared to BioAge Labs' net margin of -912.26%. BioAge Labs' return on equity of -28.99% beat Aardvark Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioAge Labs	-912.26%	-28.99%	-27.09%
Aardvark Therapeutics	N/A	-71.54%	-64.94%

Aardvark Therapeutics has lower revenue, but higher earnings than BioAge Labs. BioAge Labs is trading at a lower price-to-earnings ratio than Aardvark Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioAge Labs	$8.99M	54.12	-$80.61M	-$2.38	N/A
Aardvark Therapeutics	N/A	N/A	-$57.59M	-$3.21	N/A

BioAge Labs currently has a consensus price target of $36.57, suggesting a potential upside of 245.01%. Aardvark Therapeutics has a consensus price target of $16.30, suggesting a potential upside of 149.24%. Given BioAge Labs' stronger consensus rating and higher probable upside, equities analysts clearly believe BioAge Labs is more favorable than Aardvark Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioAge Labs	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Aardvark Therapeutics	2 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.46

In the previous week, Aardvark Therapeutics had 1 more articles in the media than BioAge Labs. MarketBeat recorded 6 mentions for Aardvark Therapeutics and 5 mentions for BioAge Labs. BioAge Labs' average media sentiment score of 1.36 beat Aardvark Therapeutics' score of 1.26 indicating that BioAge Labs is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioAge Labs	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Aardvark Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

BioAge Labs has a beta of 0.93, meaning that its share price is 7% less volatile than the broader market. Comparatively, Aardvark Therapeutics has a beta of 3.81, meaning that its share price is 281% more volatile than the broader market.

Summary

BioAge Labs beats Aardvark Therapeutics on 7 of the 13 factors compared between the two stocks.

Get Aardvark Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AARD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AARD vs. The Competition

Export

Metric	Aardvark Therapeutics	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$140.28M	$11.89B	$7.06B	$13.10B
Dividend Yield	N/A	2.70%	2.57%	10.45%
P/E Ratio	-2.04	775.15	269.06	25.28
Price / Sales	N/A	741.16	592.96	87.71
Price / Cash	N/A	66.45	70.48	50.90
Price / Book	1.91	11.60	12.91	6.24
Net Income	-$57.59M	$2.77B	$3.45B	$347.60M
7 Day Performance	-17.22%	0.17%	1.12%	1.07%
1 Month Performance	4.47%	0.35%	1.79%	1.03%
1 Year Performance	-41.92%	161.52%	67.69%	20.77%

Aardvark Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AARD Aardvark Therapeutics	2.9759 of 5 stars	$6.54 +2.0%	$16.30 +149.2%	-42.8%	$140.28M	N/A	N/A	18	Positive News Earnings Report
CRMD CorMedix	2.5447 of 5 stars	$7.44 -0.9%	$14.86 +99.7%	-32.6%	$589.17M	$311.71M	3.49	30	Trending News Earnings Report Analyst Forecast
CTNM Contineum Therapeutics	1.4123 of 5 stars	$15.04 -2.0%	$20.25 +34.6%	+120.1%	$577.48M	$50M	N/A	31	News Coverage Positive News High Trading Volume
RLMD Relmada Therapeutics	2.2604 of 5 stars	$4.94 -8.0%	$12.00 +142.9%	+736.0%	$563.26M	N/A	N/A	10	Analyst Revision
SPRY ARS Pharmaceuticals	3.4929 of 5 stars	$6.16 +11.0%	$28.20 +357.8%	-61.4%	$551.13M	$84.28M	N/A	90	Trending News Earnings Report Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AARD) was last updated on 8/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Aardvark Therapeutics (AARD) Competitors

AARD vs. CRMD, CTNM, RLMD, SPRY, and BIOA

How does Aardvark Therapeutics compare to CorMedix?

Summary

How does Aardvark Therapeutics compare to Contineum Therapeutics?

Summary

How does Aardvark Therapeutics compare to Relmada Therapeutics?

Summary

How does Aardvark Therapeutics compare to ARS Pharmaceuticals?

Summary

How does Aardvark Therapeutics compare to BioAge Labs?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AARD vs. The Competition

Aardvark Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Aardvark Therapeutics (AARD) Competitors

AARD vs. CRMD, CTNM, RLMD, SPRY, and BIOA

How does Aardvark Therapeutics compare to CorMedix?

Do analysts recommend AARD or CRMD?

Do institutionals & insiders hold more shares of AARD or CRMD?

Is AARD or CRMD more profitable?

Which has more volatility and risk, AARD or CRMD?

Does the media prefer AARD or CRMD?

Which has higher valuation & earnings, AARD or CRMD?

Summary

How does Aardvark Therapeutics compare to Contineum Therapeutics?

Does the media prefer CTNM or AARD?

Which has higher valuation & earnings, CTNM or AARD?

Do analysts rate CTNM or AARD?

Which has more risk and volatility, CTNM or AARD?

Is CTNM or AARD more profitable?

Summary

How does Aardvark Therapeutics compare to Relmada Therapeutics?

Does the media favor AARD or RLMD?

Do analysts recommend AARD or RLMD?

Which has higher valuation and earnings, AARD or RLMD?

Do institutionals and insiders hold more shares of AARD or RLMD?

Which has more risk and volatility, AARD or RLMD?

Is AARD or RLMD more profitable?

Summary

How does Aardvark Therapeutics compare to ARS Pharmaceuticals?

Which has more risk & volatility, SPRY or AARD?

Does the media favor SPRY or AARD?

Do insiders & institutionals believe in SPRY or AARD?

Is SPRY or AARD more profitable?

Which has better earnings and valuation, SPRY or AARD?

Do analysts recommend SPRY or AARD?

Summary

How does Aardvark Therapeutics compare to BioAge Labs?

Is BIOA or AARD more profitable?

Which has higher earnings and valuation, BIOA or AARD?

Do analysts rate BIOA or AARD?

Does the media prefer BIOA or AARD?

Which has more volatility & risk, BIOA or AARD?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AARD vs. The Competition

Aardvark Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools